List of Excipients in Branded Drug AZELAIC ACID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	AZELAIC ACID GEL	azelaic acid	0781-7172	1,2-DIARACHIDOYL-SN-GLYCERO-3-PHOSPHOCHOLINE
Sandoz Inc	AZELAIC ACID GEL	azelaic acid	0781-7172	BENZOIC ACID
Sandoz Inc	AZELAIC ACID GEL	azelaic acid	0781-7172	EDETATE DISODIUM
Sandoz Inc	AZELAIC ACID GEL	azelaic acid	0781-7172	MEDIUM-CHAIN TRIGLYCERIDES

Generic Drugs Containing AZELAIC ACID

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	azelaic acid	0115-1624	BENZOIC ACID
Amneal Pharmaceuticals of New York LLC	azelaic acid	0115-1624	CARBOMER HOMOPOLYMER TYPE C
Amneal Pharmaceuticals of New York LLC	azelaic acid	0115-1624	EDETATE DISODIUM
Amneal Pharmaceuticals of New York LLC	azelaic acid	0115-1624	MEDIUM-CHAIN TRIGLYCERIDES

What are the Most Frequently-Used Excipients in AZELAIC ACID?

# Of NDCs	Excipient
4	BENZOIC ACID
4	CARBOMER HOMOPOLYMER TYPE C
4	EDETATE DISODIUM
1	GLYCERYL MONOOLEATE

Azelaic Acid Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Azelaic acid is a low-cost, established topical active with broad formulation potential in acne, rosacea, post-inflammatory hyperpigmentation and cosmetic brightening. Its main development constraint is poor water solubility, while its principal commercial advantage is the ability to support multiple delivery systems without complex biologic, sterile, or cold-chain requirements. The strongest opportunities are differentiated vehicles, improved sensory performance, combination products, and region-specific OTC or prescription positioning rather than new composition-of-matter protection.

What is the pharmaceutical and commercial profile of azelaic acid?

Azelaic acid is a naturally occurring nine-carbon dicarboxylic acid with keratolytic, antimicrobial, anti-inflammatory and melanin-modulating activity. It is used topically at concentrations commonly ranging from 10% to 20%.

Attribute	Commercial relevance
Active ingredient	Azelaic acid
Chemical class	Saturated dicarboxylic acid
Common strengths	10%, 15%, and 20%
Prescription products	Azelex 20% cream; Finacea 15% gel and foam
Main indications	Acne vulgaris, inflammatory papules and pustules of rosacea
Cosmetic uses	Uneven skin tone, post-inflammatory hyperpigmentation, blemishes
Route	Topical
Biologic or biosimilar exposure	None
Cold-chain requirement	Generally none
Primary technical barrier	Low aqueous solubility and gritty or crystalline sensory profile
Main commercial barrier	Mature generic and cosmetic competition

The FDA approved Azelex cream for acne and Finacea gel and foam for rosacea. Product labels identify azelaic acid as the active ingredient and list excipients that control dispersion, viscosity, skin feel, preservation and chemical stability [1-3].

What excipient properties are required for azelaic acid formulations?

The excipient system must address four formulation problems: limited water solubility, high active loading, crystal formation and consumer tolerability.

Azelaic acid has two carboxylic acid groups and a pKa in the mid-4 range. Solubility increases when the molecule is partially ionized, but raising pH can reduce tolerability and alter the performance of the finished product. A formulation therefore has to balance pH, solubilization, suspension quality and skin compatibility.

Key formulation requirements

Requirement	Preferred excipient function
Maintain uniform active distribution	Suspending agents, rheology modifiers, structured emulsions
Reduce gritty feel	Fine particle engineering, wetting agents, controlled crystallization
Improve spreading	Emollients, esters, volatile or semi-volatile solvents
Limit irritation	Mild surfactants, buffered pH, reduced alcohol content
Control microbial growth	Preservative system or low-water formulation
Maintain physical stability	Emulsifiers, polymeric stabilizers, chelators
Support high drug loading	Water-miscible solvents, oil phases, microemulsions, gels
Improve patient adherence	Non-greasy texture, rapid drying, low residue

The most useful excipient strategy is usually a hybrid system rather than a single solubilizer. At 15% to 20% azelaic acid, complete aqueous solubilization can be difficult. A suspension or partially solubilized emulsion may provide better stability and tolerability than forcing the entire dose into solution.

Which excipients are most suitable for azelaic acid?

Solvents and co-solvents

Propylene glycol, polyethylene glycols, glycerol and related polyols can improve wetting and partial solubilization. They also affect drying time, tack and irritation. Propylene glycol is widely used in topical products but can cause irritation or sensitization in some users, particularly at elevated concentrations.

Ethoxydiglycol and similar solvent systems can improve active distribution and skin feel. Their use requires assessment of dermal safety, residual odor, packaging compatibility and regional regulatory limits.

Alcohol-based systems can improve drying and solubilization but may increase stinging, erythema and barrier disruption. They are more suitable for targeted gel or solution products than for formulations intended for sensitive rosacea-prone skin.

Emollients and oil-phase excipients

Esters, triglycerides, hydrocarbons and silicone-based emollients can reduce the dry, powdery feel associated with suspended azelaic acid. Suitable materials should have low comedogenicity risk, acceptable spreadability and minimal interaction with the preservative system.

Silicone-containing systems can produce a smoother finish and support makeup compatibility. They are commercially attractive for facial products but may require careful suspension design because changes in interfacial tension can promote sedimentation or crystal growth.

Rheology modifiers

Carbomers, acrylate copolymers, cellulose derivatives, xanthan gum and other polymers can suspend azelaic acid particles and control application thickness. Their selection affects:

• Yield stress and sedimentation resistance
• Extrudability from tubes or pumps
• Rub-in time
• Pilling under sunscreen or makeup
• Sensory residue
• Compatibility with electrolytes and pH adjusters

Carbomer systems may provide elegant gels, but neutralization and electrolyte sensitivity must be controlled. Cellulose-based systems can offer more forgiving processing but may feel tackier or heavier.

Emulsifiers and surfactants

Nonionic emulsifiers are generally preferred for sensitive-skin products because they are less likely to cause irritation than strongly ionic systems. Surfactant concentration should remain as low as practical. Excess surfactant can increase sting, disrupt the stratum corneum and reduce consumer acceptance.

Preservatives and chelators

Water-containing formulations require a validated preservative system. Phenoxyethanol, organic acids, parabens and other preservative classes may be considered based on market requirements and compatibility. Chelators such as disodium EDTA can support preservative performance and reduce metal-catalyzed degradation risks.

Preservative choice affects global commercialization because permitted materials and concentration limits vary across the United States, European Union, Asia-Pacific and other markets.

What formulations are protected by azelaic acid patents?

The commercially relevant formulation categories are creams, gels, foams, emulsions, suspensions, serums, lotions and anhydrous dispersions. Historical formulation patents have generally focused on:

• High-concentration topical compositions
• Improved solubilization
• Gel vehicles
• Foam delivery
• Reduced irritation
• Treatment of acne or rosacea
• Particle-size control
• Combination use with other dermatology actives

The original composition-of-matter protection for azelaic acid is long expired. Historical U.S. formulation and method-of-use patents associated with branded products have also reached or approached expiration, depending on the patent family and jurisdiction. Current Orange Book status must be verified by product and application because listed patents can change through regulatory updates, pediatric extensions, or product-specific submissions [4].

A new developer is more likely to obtain protection for a specific formulation architecture, manufacturing process, particle-size distribution, packaging system or combination therapy than for azelaic acid itself. Patent claims should focus on measurable technical features, such as:

• Defined particle-size ranges
• Crystal-form control
• Specific solvent ratios
• Narrow pH ranges
• Foam density or collapse time
• Improved deposition or skin penetration
• Reduced irritation at a defined drug concentration
• Stability after repeated dispensing
• Preservative-free multidose packaging

A broad claim covering “azelaic acid in a topical carrier” would face substantial validity and prior-art risk.

When does azelaic acid lose exclusivity?

Azelaic acid has no meaningful remaining U.S. active-ingredient exclusivity barrier. Azelex and Finacea are mature branded products, and generic topical azelaic acid products have been approved in the United States. Regulatory exclusivity periods associated with the original approvals have expired.

Product	Strength and dosage form	FDA status	Exclusivity position
Azelex	20% cream	Approved prescription product	Mature product; generic competition
Finacea	15% gel	Approved prescription product	Mature product; generic competition
Finacea	15% foam	Approved prescription product	Product-specific generic and formulation considerations
Cosmetic azelaic acid products	Commonly 10% or lower, depending on market	Generally cosmetic positioning	No FDA drug exclusivity if marketed without drug claims

Commercial launch timing is therefore driven by formulation development, FDA review, labeling, manufacturing readiness and potential patent certifications rather than by an expected basic-patent cliff.

What is the Orange Book status of azelaic acid products?

The Orange Book lists approved drug applications and, where applicable, patents and regulatory exclusivity. Azelex and Finacea should be reviewed by application number, dosage form and strength rather than by active ingredient alone [4].

For an abbreviated new drug application, the strategic questions are:

1. Is the reference product listed as eligible for generic substitution?
2. Are any patents listed against the specific reference product?
3. Does the applicant need a Paragraph IV certification?
4. Does the proposed product match the reference dosage form and route?
5. Is a comparative clinical endpoint study needed because of formulation complexity?

Topical semisolid products can create approval complexity even after patent expiry. The critical regulatory issue is often therapeutic equivalence and product sameness rather than chemical identity.

What Paragraph IV challenges affect azelaic acid?

Paragraph IV exposure is product-specific. A generic applicant may certify that an Orange Book-listed patent is invalid, unenforceable or not infringed. If an eligible Paragraph IV notice is filed, the reference sponsor may initiate litigation within the statutory period, potentially triggering a 30-month stay under the Hatch-Waxman framework [5].

For mature azelaic acid products, the commercial risk is more likely to involve:

• Formulation-specific patents on gel or foam systems
• Method-of-use claims covering rosacea or acne
• Patent listings that differ between cream, gel and foam presentations
• Non-infringing alternative vehicles
• ANDA approval timing and first-filer status

A developer should not assume that a patent position for Finacea gel applies to Finacea foam or Azelex cream. Each dosage form requires a separate patent and regulatory analysis.

How strong is the azelaic acid patent estate?

The core patent estate is weak because azelaic acid is an old, well-characterized molecule with extensive prior art. The strongest remaining opportunities are narrow formulation or process claims supported by comparative data.

Patent category	Relative strength	Commercial value
Composition of matter	Very low	Minimal
Broad topical composition	Low	Limited
Narrow vehicle composition	Moderate	Potentially meaningful
Foam delivery system	Moderate to high if technically specific	High for differentiated products
Particle-size or crystal control	Moderate	Useful if linked to sensory or stability benefits
Method of treating acne	Low to moderate	Dependent on claim scope and prior art
Method of treating rosacea	Low to moderate	Product-label and prior-use constraints
Packaging and dispensing system	Moderate	Useful for premium or preservative-free products
Manufacturing process	Moderate	Stronger when difficult to design around

Patent value depends heavily on enforceability and whether a competitor can reproduce the product using a different vehicle. Trade secrets may be more valuable than patents for particle processing, emulsion sequencing, foam manufacture and scale-up parameters.

What commercial opportunities exist for azelaic acid excipient innovation?

Premium sensitive-skin prescription products

A low-irritation 15% or 20% product can compete against generic creams and gels if it improves adherence. Commercial differentiation may come from reduced stinging, faster absorption, lower residue and compatibility with moisturizers or sunscreen.

Cosmetic and quasi-drug products

Lower-strength azelaic acid products can target discoloration, blemishes and uneven tone. Claims must remain within the applicable cosmetic or OTC framework. In the United States, claims to treat acne, rosacea or disease can move the product into drug regulation.

Combination products

Potential combinations include azelaic acid with niacinamide, retinoids, benzoyl peroxide, topical antibiotics, tranexamic acid or other pigment-modulating agents. Combination development raises compatibility, irritation and regulatory questions. It can also support differentiated claims if the combination produces a clinically meaningful benefit.

Foam and sprayable delivery

Foams can improve spreadability and reduce the heavy feel of a high-load cream. The technology is more difficult to manufacture and package, which can create a stronger barrier to entry than a conventional cream. The key technical targets are foam stability, dose uniformity, collapse behavior, preservative control and compatibility with the actuator and container.

Anhydrous and low-water systems

Anhydrous dispersions and low-water emulsions can reduce microbial risk and simplify preservation. They may also improve stability, but they can produce a waxy or oily sensory profile. These systems are best suited to barrier-supportive products or targeted hyperpigmentation products where rich texture is acceptable.

Regional licensing and contract development

Licensing opportunities are more likely to involve a proprietary topical platform than the azelaic acid molecule. Potential deal assets include:

• Patented foam or microemulsion technology
• Preservative-free multidose packaging
• Dermatology-focused contract manufacturing
• Regional rights for prescription or cosmetic products
• Combination formulations supported by clinical data
• Particle-engineering technology that improves sensory performance

The strongest licensing proposition combines a defensible formulation patent with manufacturing know-how and data showing improved tolerability or adherence.

What generic entry risks exist for azelaic acid?

Generic entry risk is high for conventional creams and gels because the active is inexpensive, the therapeutic area is established and multiple excipient systems can likely achieve comparable performance. Risk is lower for technically complex foams, controlled particle systems and formulations with difficult-to-replicate microstructure.

Product strategy	Generic risk	Differentiation potential
Conventional 20% cream	High	Low
Standard 15% gel	High	Low to moderate
Foam	Moderate	Moderate to high
Preservative-free pump	Moderate	Moderate
Microemulsion or nanosuspension	Moderate	High if clinically superior
Combination product	Moderate	High, subject to regulatory pathway
Cosmetic 10% serum	High	Moderate through brand and sensory performance

A branded product without meaningful formulation or clinical differentiation is exposed to price erosion. Manufacturing scale and supply reliability become more important as the market commoditizes.

How does azelaic acid compare with competing topical actives?

Active	Primary positioning	Formulation advantage	Main limitation
Azelaic acid	Acne, rosacea, hyperpigmentation	Broad use profile and good chemical stability	Irritation and poor aqueous solubility
Niacinamide	Barrier support, pigmentation, acne adjunct	Highly water-compatible	Less suitable as a sole prescription acne treatment
Tretinoin	Acne and photoaging	Established efficacy	Irritation, light sensitivity and stability concerns
Benzoyl peroxide	Acne antimicrobial	Strong established efficacy	Oxidative instability and irritation
Hydroquinone	Hyperpigmentation	Potent pigment reduction	Regulatory and safety restrictions in some markets
Salicylic acid	Acne and keratolysis	Easy incorporation into many vehicles	Dryness and irritation at higher exposure

Azelaic acid has a favorable commercial position where consumers want one active that addresses acne, redness and discoloration. Its formulation challenge is greater than that of niacinamide but less complex than many biologic or peptide delivery systems.

What FDA regulatory status and manufacturing barriers apply?

Azelaic acid is regulated as an approved topical drug in prescription products and may be marketed in cosmetic products when claims and concentrations comply with applicable rules. The FDA product label, application history, Orange Book listing and current manufacturing requirements should be reviewed for each target product [1-4].

Manufacturing barriers are moderate. The active is not intrinsically difficult to synthesize at commercial scale, but the finished product can be difficult to control. Critical process parameters include:

• Milling and particle-size distribution
• Wetting and dispersion order
• Temperature during emulsification
• Shear rate and mixing time
• Neutralization sequence
• Homogenization
• Filling temperature
• Container-closure compatibility

Quality attributes should include assay, content uniformity, particle size, rheology, pH, microbial limits, preservative effectiveness, appearance, odor, spreadability and in-use stability.

Key Takeaways

• Azelaic acid has no meaningful remaining composition-of-matter exclusivity barrier.
• The main technical problem is high-load topical formulation, not API synthesis.
• Creams and gels face high generic competition; foams, microemulsions and low-irritation systems offer stronger differentiation.
• Excipient selection should prioritize dispersion, particle control, sensory performance and irritation reduction.
• Narrow formulation, particle-engineering, packaging and manufacturing claims are more defensible than broad topical composition claims.
• Biosimilar risk does not apply because azelaic acid is a small-molecule topical drug.
• The strongest commercial opportunities are premium dermatology products, cosmetic brightening products, combination formulations and proprietary delivery platforms.
• Orange Book and Paragraph IV analysis must be conducted separately for Azelex cream, Finacea gel and Finacea foam.
• Manufacturing know-how may provide greater practical protection than a broad patent estate.
• Revenue exposure is highest for undifferentiated branded creams and gels after generic entry.

FAQs

Can azelaic acid be formulated as a water-based serum?

Yes, but a true aqueous solution at commercially useful concentration may be difficult. A suspension, microemulsion or solvent-assisted system is more practical. The formulation must control crystallization, grittiness and pH-related irritation.

Is azelaic acid compatible with niacinamide?

Generally, yes. The combination can support acne and pigmentation positioning, but the finished product requires testing for pH compatibility, stability, preservative performance and consumer tolerability.

Does azelaic acid require a penetration enhancer?

No. A penetration enhancer is optional rather than essential. Its use can improve delivery but may increase irritation, systemic exposure or regulatory complexity.

Are azelaic acid cosmetic products patentable?

Yes, but patentability depends on the claimed formulation, process or technical effect. A generic claim covering azelaic acid in a cosmetic vehicle is vulnerable to prior art. Specific particle, solvent, packaging or stability claims are more defensible.

Is azelaic acid suitable for an OTC drug strategy?

It can support an OTC or cosmetic strategy depending on the jurisdiction, concentration, claims and regulatory classification. In the United States, disease-treatment claims can trigger drug regulation even when the product is sold through cosmetic channels.

References

1. U.S. Food and Drug Administration. (2023). Azelex (azelaic acid) cream, 20% prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2023). Finacea (azelaic acid) gel, 15% prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2023). Finacea (azelaic acid) foam, 15% prescribing information. FDA/DailyMed.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. FDA.